- Aktuelle Seite:
-
Home
-
Harm Reduction / Schadensminderung
- Naloxon
USA. Allowing Pharmacists to Directly Dispense Opioid Antidote Can Sharply Cut Opioid Overdose Deaths
Allowing pharmacists to dispense the opioid antidote naloxone without a physician's prescription can sharply reduce the incidence of fatal opioid-related overdoses, according to a new RAND Corporation study.
States that adopted such laws saw fatal opioid overdoses fall by an average of 27 percent during the second year following passage and 34 percent in subsequent years, according to the study published in the journal JAMA Internal Medicine. (RAND, USA, 06.05.2019)
https://www.rand.org/news/press/2019/05/06.html
Does Take-Home Naloxone Availability Increase Opioid Use?.
Tas, B., Humphreys, K., McDonald, R., and Strang, J. ( 2019)
Addiction, doi.org/10.1111/add.14637.
https://onlinelibrary.wiley.com/doi/epdf/10.1111/add.14637
USA. FDA approves first generic naloxone nasal spray to treat opioid overdose
Agency is also taking new steps to support development of over-the-counter and additional generics of naloxone to help reduce opioid overdose deaths, increase access to emergency treatment. (FDA – US Fodd and Drug Administration, 19.04.2019)
Evidence-Based Guidelines for EMS Administration of Naloxone.
Williams K, Lang ES, Panchal A, Gasper JJ, Taillac P, Gouda J, Hedges M.
Prehosp Emerg Care. 2019 Mar 29:1-41. doi: 10.1080/10903127.2019.1597955.
https://www.tandfonline.com/doi/full/10.1080/10903127.2019.1597955
Comparative Human Factors Evaluation of Two Nasal Naloxone Administration Devices: NARCAN® Nasal Spray and Naloxone Prefilled Syringe with Nasal Atomizer.
Tippey KG, Yovanoff M, McGrath LS, Sneeringer P.
Pain Ther. 2019 Mar 15. doi: 10.1007/s40122-019-0118-0.
https://link.springer.com/article/10.1007%2Fs40122-019-0118-0
Intranasal naloxone rapidly occupies brain mu-opioid receptors in human subjects.
Johansson J, Hirvonen J, Lovró Z, Ekblad L, Kaasinen V, Rajasilta O, Helin S, Tuisku J, Sirén S, Pennanen M, Agrawal A, Crystal R, Vainio PJ, Alho H, Scheinin M.
Neuropsychopharmacology. 2019 Mar 13. doi: 10.1038/s41386-019-0368-x.
Abstract
https://www.ncbi.nlm.nih.gov/pubmed/30867551
Evaluation and optimization of take-home naloxone in an academic medical center.
Cooler J, Ross CA, Robert S, Linder L, Ruhe AM, Philip A.
Ment Health Clin. 2019 Mar 1;9(2):105-109. doi: 10.9740/mhc.2019.03.105.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6398357/
USA. Next-generation single-dose antidotes for opioid overdoses.
American Chemical Society. (ScienceDaily, USA, 31.03.2019)
https://www.sciencedaily.com/releases/2019/03/190331192537.htm
Opioid Overdose Reversal News: FDA-approved naloxone devices produce substantially higher blood levels of naloxone than improvised nasal spray
(...) A new study looked at how well the FDA-approved nasal spray and autoinjector compared to the improvised nasal devices, which are not FDA-approved. Scientists found that the approved naloxone devices deliver higher blood levels of naloxone than the improvised nasal devices. In fact, levels in the plasma concentration of naloxone are considerably lower when improvised devices are used. The FDA-approved 4-mg dose nasal spray produced the highest blood level of naloxone of all the products tested. (NIDA, USA, 15.03.2019)
Heroin body-packing and naloxone
Vahabzadeh, Maryam et al.
The Lancet , Volume 393 , Issue 10177 , e35
(Registrierung erforderlich)
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)30502-1/fulltext
The effects of heat and freeze-thaw cycling on naloxone stability
Dulcie Lai, Amy Trinh Pham, Praveen P. Nekkar Rao and Michael A. Beazely
Harm Reduction Journal 2019, 16:17, doi.org/10.1186/s12954-019-0288-4
https://harmreductionjournal.biomedcentral.com/articles/10.1186/s12954-019-0288-4
Kratom (Mitragynine) Ingestion Requiring Naloxone Reversal.
Overbeek DL, Abraham J, Munzer BW.
Clin Pract Cases Emerg Med. 2019 Jan 4;3(1):24-26. doi: 10.5811/cpcem.2018.11.40588.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6366391/
A novel naloxone training compared with current recommended training in an overdose simulation.
Franko TS 2nd, Distefano D, Lewis L.
J Am Pharm Assoc (2003). 2019 Feb 8. pii: S1544-3191(18)30590-9. doi: 10.1016/j.japh.2018.12.022.
Abstract
https://www.ncbi.nlm.nih.gov/pubmed/30745190
Elective Naloxone-Induced Opioid Withdrawal for Rapid Initiation of Medication-Assisted Treatment of Opioid Use Disorder.
Phillips RH, Salzman M, Haroz R, Rafeq R, Mazzarelli AJ, Pelletier-Bui A.
Ann Emerg Med. 2019 Feb 14. pii: S0196-0644(19)30006-X. doi: 10.1016/j.annemergmed.2019.01.006.
Abstract
https://www.ncbi.nlm.nih.gov/pubmed/30773411
Higher doses of naloxone are needed in the synthetic opiod era
Ronald B. Moss and Dennis J. Carlo
Substance Abuse Treatment, Prevention, and Policy, 2019, 14:6, doi.org/10.1186/s13011-019-0195-4
https://substanceabusepolicy.biomedcentral.com/articles/10.1186/s13011-019-0195-4
USA. FDA may recommend overdose reversal drug alongside opioid prescriptions
In a growing number of states, patients who get opioids for serious pain may leave their doctors' offices with a second prescription -- for naloxone, a drug that can save their lives if they overdose on the powerful painkillers. (CNN, USA, 20.02.2019)
https://edition.cnn.com/2019/02/20/health/opioids-naloxone-prescriptions-partner/index.html
Pharmacokinetics of a novel, approved, 1.4 mg intranasal naloxone formulation for reversal of opioid overdose - a randomised controlled trial.
Skulberg AK, Åsberg A, Khiabani HZ, Røstad H, Tylleskar I, Dale O.
Addiction. 2019 Jan 14. doi: 10.1111/add.14552.
Abstract
https://www.ncbi.nlm.nih.gov/pubmed/30644628
Take-home naloxone: a life saver in opioid overdose
The Lancet , Volume 393 , Issue 10169 , 296
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)30153-9/fulltext
Scotland's National Naloxone Programme
Bird, Sheila M et al.
The Lancet , Volume 393 , Issue 10169 , 316 - 318
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)33065-4/fulltext
USA. FDA Takes Step to Allow Drug Companies to Sell Naloxone Without Prescription
USA. FDA Takes Step to Allow Drug ComThe U.S. Food and Drug Administration (FDA) has taken a step to make it easier for companies that make the opioid overdose antidote naloxone to sell the drug without a prescription, CNBC reports. Making naloxone available over-the-counter would lower costs and increase consumer access, the agency said. (drugfree.org, USA, 24.01.2019)
USA. Design team creates a naloxone dispenser
(...) Claudia B. Rebola, graduate studies coordinator in UC's College of Design, Architecture, Art, and Planning (DAAP), designed a device to make naloxone more accessible to those in need. Her intent is to bring a model she helped create first in Providence, Rhode Island, to spaces in Cincinnati by spring.
An associate professor in DAAP's Myron E. Ullman, Jr. School of Design, Rebola has worked with graduate students to create AntiOD, a naloxone-dispensing smart device installed in semi-public places with step-by-step instructions for bystanders. Looking at a broader view of educating the public, Rebola's team has also created an informational campaign to train the public on signs of overdose and how to help. (MedicalXpress, USA, 22.01.2019)
https://medicalxpress.com/news/2019-01-team-naloxone.html
USA. FDA Statement: Statement from FDA Commissioner Scott Gottlieb, M.D., on unprecedented new efforts to support development of over-the-counter naloxone to help reduce opioid overdose deaths
(...) To encourage drug companies to enter the OTC market and increase access to naloxone, the FDA took an unprecedented step: we developed a model DFL with easy-to-understand pictograms on how to use the drug. We also conducted label comprehension testing to ensure the instructions were simple to follow. (FDA - U.S. Food and Drug Administration, 17.01.2019)
https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm629571.htm
USA. FDA Moves to Fast-Track OTC Naloxone for Opioid Overdose
The US Food and Drug Administration (FDA) today announced "unprecedented" steps to support companies in developing over-the-counter (OTC) naloxone to help reduce opioid overdose deaths. (Medscape, 17.01.2019)
https://www.medscape.com/viewarticle/907885
Australien. An update on take-home naloxone knowledge amongst people who inject drugs
The Illicit Drug Reporting System (IDRS) is an ongoing illicit drug monitoring system which has been conducted in all states and territories of Australia since 2000, and forms part of Drug Trends.
Naloxone is an opioid antagonist that is a safe and effective agent for reversing the effects of opioids, such as heroin and morphine. Since 2012, take-home programs have been established to make naloxone more widely available so that it can be administered by people other than medical professionals.
Using IDRS data from 2013 to 2018, this briefing note aims to examine knowledge of these take-home programs and naloxone more broadly, among a sample of PWID recruited as part of the IDRS in Victoria, Australia. (NDARC – National Drug & Alcohol Research Center, Australien, Januar 2019)
After naloxone, when can opioid overdose patients be safely discharged?
Naloxone has saved thousands of lives. But can patients be safely discharged from the Emergency Department (ED) just an hour after they receive the medication that curtails drug overdoses? (University at Buffalo, USA, 02.01.2019)
https://medicalxpress.com/news/2018-12-naloxone-opioid-overdose-patients-safely.html
Hospital Observation Upon Reversal (HOUR) With Naloxone: A Prospective Clinical Prediction Rule Validation Study
Brian M. Clemency DO, William Eggleston PharmD, Evan W. Shaw, Michael Cheung, Nicholas S. Pokoj, Michael A. Manka MD, Donald J. Giordano, Laura Serafin, Han Yu MA, Heather A. Lindstrom PhD, David Hostler PhD
Academic Emergency Medicine 2018;00:1–9. First published: 28 December 2018, doi.org/10.1111/acem.13567
https://onlinelibrary.wiley.com/doi/10.1111/acem.13567
Kanada. Drug users, families advised to keep naloxone kits handy
Island Health is advising illicit drug users and their family and friends to keep life-saving naloxone kits close at hand. (Times Colonist, Kanada, 16.12.2018)
USA. Drug company to offer cheaper opioid overdose treatment after hiking price 600 percent
(...) A report from the Senate’s Permanent Subcommittee on Investigations last month found that the company, Kaléo, hiked the price of its drug Evzio to $4,100 for two injectors, raising the price by more than 600 percent between 2014 and 2017. (The Hill, USA, 12.12.2018)
USA. Generic Opioid Overdose Antidote Treatment to be Available in 2019
An authorized generic for kaléo’s naloxone HCl injection (Evzio®) will be availabile midyear in 2019, and will come with a list price of $178 per carton, each containing 2 auto-injectors. Offered through kaléo subsidiary IJ Therapeutics, the new authorized generic is the same formulation and design as the branded drug, but will have a different label. (Pharmacy Times, USA, 13.12.2018)
Naloxone distribution and possession following a large-scale naloxone programme.
Madah-Amiri, D., Gjersing, L., and Clausen, T. (2019)
Addiction, 114: 92–100., doi.org/10.1111/add.14425.
https://onlinelibrary.wiley.com/doi/10.1111/add.14425
Seite 1 von 7